RecruitingPhase 4NCT05858645

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Sponsor

University of California, San Francisco

Enrollment

25 participants

Start Date

Oct 1, 2023

Study Type

INTERVENTIONAL

Conditions

Psoriasis Vulgaris

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called deucravacitinib for people with psoriasis vulgaris. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.